CombiMatrix Corp (CBMX)

7.40
NASDAQ : Health Care
Prev Close 7.35
Day Low/High 7.30 / 7.50
52 Wk Low/High 2.15 / 7.90
Avg Volume 105.90K
Exchange NASDAQ
Shares Outstanding 2.92M
Market Cap 21.45M
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Invitae Acquiring Good Start Genetics And CombiMatrix, Adding Comprehensive Reproductive Health Capabilities To Serve Every Stage Of Life

Invitae Acquiring Good Start Genetics And CombiMatrix, Adding Comprehensive Reproductive Health Capabilities To Serve Every Stage Of Life

-- Good Start Genetics Provides Best-in-Class Carrier and NGS Preimplantation Screening to Leading IVF Centers --

CombiMatrix Notes Decision By Health Care Service Corporation To Reimburse For Recurrent Pregnancy Loss Testing

CombiMatrix Notes Decision By Health Care Service Corporation To Reimburse For Recurrent Pregnancy Loss Testing

Trend continues by health providers to cover chromosomal microarray testing for recurrent pregnancy loss

CombiMatrix Announces Distribution Agreement With Universal Diagnostic Laboratories For Miscarriage Analysis Testing

CombiMatrix Announces Distribution Agreement With Universal Diagnostic Laboratories For Miscarriage Analysis Testing

Agreement expands access to CombiMatrix's test for women in the state of California

CombiMatrix Study Published In Genetics In Medicine Establishes The Superior Diagnostic Value Of Microarray Analysis Over Karyotyping For Recurrent Pregnancy Loss Testing

CombiMatrix Study Published In Genetics In Medicine Establishes The Superior Diagnostic Value Of Microarray Analysis Over Karyotyping For Recurrent Pregnancy Loss Testing

Data further validates CombiMatrix's microarray testing for miscarriage analysis and supports position as commercial and scientific leader in the $300 million annual U.S. market

CombiMatrix Launches Next Generation Sequencing For Pre-Implementation Genetic Screening

CombiMatrix Launches Next Generation Sequencing For Pre-Implementation Genetic Screening

High sensitivity and specificity PGS testing by Next Generation Sequencing supports healthy pregnancies and builds on prenatal diagnostics portfolio

CombiMatrix Comments On Additional Medical Policy Revisions To Reimburse For Recurrent Pregnancy Loss Testing

CombiMatrix Comments On Additional Medical Policy Revisions To Reimburse For Recurrent Pregnancy Loss Testing

Genetic testing now categorized by six additional health plans as medically necessary for the evaluation of pregnancy loss in specific cases

CombiMatrix Notes Two Additional Blue Cross Blue Shield Health Plans Revise Medical Policies To Reimburse For Recurrent Pregnancy Loss Testing

CombiMatrix Notes Two Additional Blue Cross Blue Shield Health Plans Revise Medical Policies To Reimburse For Recurrent Pregnancy Loss Testing

Seven health plans in 2016 announce coverage for chromosomal microarray testing for recurrent pregnancy loss

CombiMatrix Provides Strategic Update

CombiMatrix Provides Strategic Update